<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26908" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pentamidine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hafiz</surname>
            <given-names>Sumaiya</given-names>
          </name>
          <aff>Cleveland Clinic Abu Dhabi</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kyriakopoulos</surname>
            <given-names>Chris</given-names>
          </name>
          <aff>University Hospital of Ioannina</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sumaiya Hafiz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chris Kyriakopoulos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26908.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pentamidine is a medication used in the management and treatment of Pneumocystis pneumonia, leishmaniasis, and trypanosomiasis. It is in the anti-infective (fungal/protozoal) class of drugs. This activity outlines the indications, action, and contraindications for pentamidine as a valuable agent in the treatment and prophylaxis of Pneumocystis pneumonia, leishmaniasis, and trypanosomiasis. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the treatment of patients with Pneumocystis pneumonia, leishmaniasis, and trypanosomiasis, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of pentamidine.</p></list-item><list-item><p>Describe the potential adverse effects of pentamidine.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving pentamidine.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance patients care and improve outcomes when using pentamidine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26908&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26908">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26908.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Pentamidine is a broad-spectrum anti-infective agent active against several parasitic worms, protozoa, and fungi.&#x000a0;It has been used in the treatment of&#x000a0;<italic toggle="yes">Pneumocystis jiroveci</italic> pneumonia in the immunocompromised, leishmaniasis (cutaneous and visceral), and human African trypanosomiasis (African sleeping sickness).&#x000a0;It is a relatively toxic drug and requires careful monitoring during therapy.&#x000a0;</p>
        <p>FDA Indications:</p>
        <p>Pentamidine isethionate is used in the treatment and prevention of&#x000a0;&#x000a0;<italic toggle="yes">Pneumocystis&#x000a0;jirovecii</italic>&#x000a0;pneumonia in high-risk, HIV-infected patients who meet the following criteria :</p>
        <list list-type="order">
          <list-item>
            <p>A history of one or more previous episodes of <italic toggle="yes">Pneumocystis jiroveci</italic> pneumonia</p>
          </list-item>
          <list-item>
            <p>A CD4+ count of 200 cells/mm^3 or less</p>
          </list-item>
        </list>
        <p>Due to its various toxicities, its use is only&#x000a0;for severe <italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia, which has&#x000a0;failed to respond to other first-line agents.</p>
        <p>Non-FDA approved indications :</p>
        <p>Anti Protozoal and Anti Parasitic action: Pentamidine is a treatment for protozoal infections such as cutaneous and visceral leishmaniasis caused by the&#x000a0;bite of phlebotomine sand flies.</p>
        <p>It is also used to treat a tropical disease like sleeping sickness, known as human African trypanosomiasis, caused by the bite of an infected tsetse fly.<xref ref-type="bibr" rid="article-26908.r1">[1]</xref><xref ref-type="bibr" rid="article-26908.r2">[2]</xref> The causative parasites of this disease are <italic toggle="yes">Trypanosoma brucei rhodesiense</italic> and <italic toggle="yes">Trypanosoma brucei&#x000a0;gambiense</italic>. It is the drug of choice for stage 1 (hemolymphatic stage) of sleeping sickness caused by <italic toggle="yes">Trypanosoma brucei&#x000a0;gambiense.</italic></p>
      </sec>
      <sec id="article-26908.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Pentamidine&#x000a0;is an&#x000a0;aromatic diamidine drug consisting of pentane-1,5-diol, which&#x000a0;interferes with polyamine synthesis, RNA polymerase activity,&#x000a0; enters the protozoal cell binding to transfer RNA, and&#x000a0;prevents the synthesis&#x000a0;of protein, nucleic acids, phospholipids, and folate. Additionally, it is known to be an anti-inflammatory agent, xenobiotic, and an antagonist of the NMDA&#x000a0;receptor, histone acetyltransferase, and calmodulin.<xref ref-type="bibr" rid="article-26908.r3">[3]</xref><xref ref-type="bibr" rid="article-26908.r4">[4]</xref></p>
      </sec>
      <sec id="article-26908.s4" sec-type="Administration">
        <title>Administration</title>
        <p>It is used in various forms, such as&#x000a0;inhalational, intravenously, or intramuscularly. It is not available in oral form, as it is poorly absorbed orally.</p>
        <p>It undergoes metabolism in the liver and has a half-life of 10&#x000a0;to 14 days.</p>
        <p>
<bold>Pneumocystis Pneumonia&#x000a0;</bold>
</p>
        <p>Treatment - the&#x000a0;recommended regimen is 3&#x000a0;to 4 mg/kg once a day, intravenous or intramuscularly, for 2&#x000a0;to 3 weeks (14&#x000a0;to 21 days).</p>
        <p>Prevention- the recommended regimen is 300 mg in a nebulized form every four weeks, or 4mg/kg intravenous/intramuscularly, once every month.&#x000a0; &#x000a0;</p>
        <p>
<bold>Leishmaniasis&#x000a0;</bold>
</p>
        <p><bold>Cutaneous leishmaniasis:</bold>&#x000a0;</p>
        <p>Daily once or every alternate day, 2 to 3 mg per kg doses for four to seven days Intramuscular or Intravenous is recommended by the CDC (Centre for disease control and prevention).&#x000a0;</p>
        <p>
<bold>Visceral leishmaniasis:</bold>
</p>
        <p>2 to 4 mg/kg intramuscular/intravenous, daily once or alternate days for fifteen days. Alternatively, 4mg per kg (IM/IV) can be given three times weekly, based on patient response to the medication for five weeks or more.&#x000a0;</p>
        <p>
<bold>Trypanosomiasis (</bold>
<bold>
<italic toggle="yes">Trypanosoma brucei&#x000a0;gambiense</italic>
<bold>)</bold>
</bold>
</p>
        <p>Used in the first stage of the disease as the drug of choice: 4 mg per kg per day Intramuscular/Intravenously for seven to ten days.<xref ref-type="bibr" rid="article-26908.r5">[5]</xref></p>
      </sec>
      <sec id="article-26908.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Due to its mechanism of action, which includes inhibition of protein and RNA synthesis and antagonism of receptors, pentamidine affects multiple organs producing various adverse effects.</p>
        <list list-type="bullet">
          <list-item>
            <p>Endocrine - Most commonly, it causes hypoglycemia due to pancreatic islet cell damage and very rarely hyperglycemia.</p>
          </list-item>
          <list-item>
            <p>Cardiology - hypotension, arrhythmias including twisting of peaks (torsades&#x000a0;de pointes), fast or abnormal heart rate, and prolonged QT interval&#x000a0;<xref ref-type="bibr" rid="article-26908.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>General - fatigue, dysgeusia (bad taste),&#x000a0;anaphylaxis, night sweats, anorexia, nausea, vomiting, syncope, rash</p>
          </list-item>
          <list-item>
            <p>Nephrological - nephrotoxicity, electrolyte imbalances such as hyperkalemia, hypocalcemia, hypomagnesemia</p>
          </list-item>
          <list-item>
            <p>Hematological - most commonly leukopenia, thrombocytopenia, and less commonly anemia can occur</p>
          </list-item>
          <list-item>
            <p>Gastroenterological and hepatological - hepatotoxicity (most commonly elevation of serum aminotransferase), pancreatitis</p>
          </list-item>
          <list-item>
            <p>Neurological -&#x000a0; neuropathy such as tingling or numbness, headache, altered mental status&#x000a0;<xref ref-type="bibr" rid="article-26908.r7">[7]</xref><xref ref-type="bibr" rid="article-26908.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Injection form - Local pain or abscess formation at the&#x000a0;site of injection</p>
          </list-item>
          <list-item>
            <p>Inhaled form -&#x000a0;bronchospasm, wheezing, and cough&#x000a0;<xref ref-type="bibr" rid="article-26908.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26908.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Previous history of an anaphylactic reaction to pentamidine in inhaled or parenteral form</p>
          </list-item>
          <list-item>
            <p>The use of pentamidine with other nephrotoxic drugs like cyclosporine, cisplatin, aminoglycoside antibiotics, beta-lactam antibiotics, amphotericin B, and indomethacin should be closely monitored or avoided.<xref ref-type="bibr" rid="article-26908.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Prolonged QT&#x000a0;interval may result with concurrent use of antiarrhythmics, antihistamines, antipsychotics, antidepressants,&#x000a0;neuroleptics, atypical antipsychotics, antibiotics (quinolone, macrolides), antimalarials, and antifungals; concurrent use could result in torsades&#x000a0;de pointes.<xref ref-type="bibr" rid="article-26908.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Pregnancy category C risk. Adequate data is currently unavailable to assess the risk of pentamidine use in pregnant women and nursing mothers.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In nursing mothers, it is advisable to discontinue breastfeeding or stop taking the drug if an alternative is available as the risk to the child is unknown.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26908.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The following investigations are necessary before initiating therapy, during the administration of the drug, and after treatment to monitor the drug and its toxicity:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Kidney function testing including serum creatinine and blood urea nitrogen</p>
          </list-item>
          <list-item>
            <p>Blood glucose measurement - to check for hypoglycemia or hyperglycemia</p>
          </list-item>
          <list-item>
            <p>Full blood count and platelet count</p>
          </list-item>
          <list-item>
            <p>Liver function test&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Serum bilirubin, alkaline phosphatase</p>
          </list-item>
          <list-item>
            <p>Electrolytes (potassium, calcium, sodium, magnesium)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>ECG - to check for arrhythmias</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26908.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <list list-type="bullet">
          <list-item>
            <p>Pentamidine is known to cause an elevation in serum aminotransferase levels during therapy.</p>
          </list-item>
          <list-item>
            <p>Other findings in pentamidine toxicity include - Hypotension, clinically apparent hepatic dysfunction, pancreatitis, renal impairment, which can cause a rise in serum creatinine, cardiopulmonary arrest, and leucopenia.</p>
          </list-item>
          <list-item>
            <p>According to a previously published study, charcoal hemoperfusion has previously been&#x000a0;employed as an antidote for overdose or toxicity.<xref ref-type="bibr" rid="article-26908.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Due to the multi-organ toxicities caused by pentamidine, it is not a commonly chosen therapy except in conditions where other first or second-line agents have failed to respond.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26908.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pentamidine is used in pneumocystis&#x000a0;pneumonia, leishmaniasis, and first-line agent for Stage 1 of trypanosomiasis caused by <italic toggle="yes">T. gambiense</italic>. The drug is available in nebulized (inhaled) and intramuscular or intravenous injection forms.&#x000a0;Healthcare workers such as doctors and nurses caring for patients who require the drug should closely monitor the patients for signs of adverse effects of the drug, which are quite common due to its multiple mechanisms of action, which cause multiorgan toxicities. Additionally, as there is currently no proven antidote for the drug, appropriate measures should be taken to counteract the effects of toxicity; an infectious disease specialty pharmacist is a valuable asset for consultation when using pentamidine, especially when the patient is on a number of other medications. This interprofessional healthcare team approach can maximize therapeutic outcomes while minimizing interactions and adverse effects. [Level 5]</p>
        <p>Studies show differences in efficacy related to the dose, making it essential to prescribe adequate doses and administer them accordingly to prevent harmful effects.</p>
        <p>In the event of hepatotoxicity or renal impairment, specialists should be involved to monitor progress, and if a nephrotoxic drug is required, the patient requires close monitoring to prevent deterioration.</p>
        <p>Injection site abscesses and infections should be cared for and treated accordingly.</p>
        <p>Instructions for the inhaled form should be explained to the patient and administered efficiently to ensure maximum drug delivery.</p>
      </sec>
      <sec id="article-26908.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26908&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26908">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26908/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26908">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26908.s11">
        <title>References</title>
        <ref id="article-26908.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Dalal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Makii</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Tolerability of Aerosolized Versus Intravenous Pentamidine for Pneumocystis jirovecii Pneumonia Prophylaxis in Immunosuppressed Pediatric, Adolescent, and Young Adult Patients.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-116</page-range>
            <pub-id pub-id-type="pmid">32071585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <chapter-title>Pentamidine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31644251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Block</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pentamidine, an inhibitor of spinal flexor reflexes in rats, is a potent N-methyl-D-aspartate (NMDA) antagonist in vivo.</article-title>
            <source>Neurosci Lett</source>
            <year>1993</year>
            <month>Jun</month>
            <day>11</day>
            <volume>155</volume>
            <issue>2</issue>
            <fpage>208</fpage>
            <page-range>208-11</page-range>
            <pub-id pub-id-type="pmid">7690919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Imaizumi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of constitutive nitric oxide synthase in the brain by pentamidine, a calmodulin antagonist.</article-title>
            <source>Eur J Pharmacol</source>
            <year>1995</year>
            <month>Apr</month>
            <day>28</day>
            <volume>289</volume>
            <issue>2</issue>
            <fpage>299</fpage>
            <page-range>299-304</page-range>
            <pub-id pub-id-type="pmid">7542607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dorlo</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Kager</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Pentamidine dosage: a base/salt confusion.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2008</year>
            <month>May</month>
            <day>28</day>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>e225</fpage>
            <pub-id pub-id-type="pmid">18509543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wharton</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Demopulos</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Goldschlager</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Torsade de pointes during administration of pentamidine isethionate.</article-title>
            <source>Am J Med</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>83</volume>
            <issue>3</issue>
            <fpage>571</fpage>
            <page-range>571-6</page-range>
            <pub-id pub-id-type="pmid">3499072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quinn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fannin</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Sciasci</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bragg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carias</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crews</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Gregornik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jeha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pauley</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">29866879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pohlig</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bernhard</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mpanya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lubaki</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mpoto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Munungu</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>N'tombe</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Deo</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Mutantu</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Kuikumbi</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Mintwo</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Munungi</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Dala</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Macharia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bilenge</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Mesu</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dituvanga</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Tidwell</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>e0004363</fpage>
            <pub-id pub-id-type="pmid">26882015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendoza</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Nephrotoxic drugs.</article-title>
            <source>Pediatr Nephrol</source>
            <year>1988</year>
            <month>Oct</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>466</fpage>
            <page-range>466-76</page-range>
            <pub-id pub-id-type="pmid">3153061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nachimuthu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Assar</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Schussler</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced QT interval prolongation: mechanisms and clinical management.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>241</fpage>
            <page-range>241-53</page-range>
            <pub-id pub-id-type="pmid">25083239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26908.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watts</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Zurlinden</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Waldo</surname>
                <given-names>FB</given-names>
              </name>
            </person-group>
            <article-title>Effect of charcoal hemoperfusion on clearance of pentamidine isethionate after accidental overdose.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1997</year>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-92</page-range>
            <pub-id pub-id-type="pmid">9022658</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
